CGX1321: Clinical Trials

2 trials of CGX1321, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 unknown. 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 12Unknown 2

Follow CGX1321: new trials by email Literature Review of CGX1321 trials Research Report on CGX1321

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
CGX1321 - Colorectal Adenocarcinoma, Gastric Adenocarcinoma
Phase 1UnknownCuregenix Inc.392017-06-172020-07-24
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
CGX1321, Pembrolizumab, encorafenib - Solid Tumors, GI Cancer
Phase 1UnknownCuregenix Inc.722016-02-012022-01-26

Conditions studied

Gastrointestinal Neoplasms (2)  ·  Bile Duct Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Esophageal Neoplasms (1)

Sponsors

Curegenix Inc. (2)

Countries

China (1)  ·  Taiwan (1)  ·  United States (1)